YUXI Jiuzhou Biotechnology Co., Ltd.

To verify the efficacy and safety of equine tetanus immune globulin (F(ab')2) for short-term passive immunization against tetanus infection.

To clarify the time course of the drug in the body after a single administration of equine tetanus immunoglobulin (F(ab')2) to healthy subjects, clarify the pharmacokinetic characteristics of this drug in humans, and compare it with the marketed equine tetanus immunoglobulin to provide a basis for clinical use; at the same time, collect the skin test positivity rate and adverse events such as allergies during the entire trial, and conduct medical evaluation laboratory safety inspections to monitor the safety of the entire process.

Using the marketed equine tetanus immunoglobulin (F(ab')2) and tetanus antitoxin injection as positive controls, the skin test positivity rate of the subjects cross-using the equine tetanus immunoglobulin (F(ab')2) produced by Yuxi Jiuzhou Biotechnology Co., Ltd. was observed to examine the safety of the drug and provide reference data for the design of later clinical trial protocols.